Monday, October 3, 2022


Biotechnology News Magazine

Ciloa Secures €5 Million

To pursue its development programs for exosome-based biomedicines and vaccines

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Ciloa, a pioneer company expert in the in vivo customization of exosomes, announced today that it has secured €5 million to pursue its development programs for exosome-based biomedicines and vaccines. These funds will be used notably for the development of a new generation of natural vaccines using exosomes to prevent SARS-CoV-2 infection, including the variants responsible for the severe form of Covid-19.

Ciloa is developing its innovative vaccine using its unique and proprietary exosome modification technology platform for the development of a new class of biologics. Exosomes are extracellular nanovesicles produced and used as natural messengers by all living organisms.

Ciloa will develop this new generation of vaccines, which will eventually target several major viruses that have no effective treatment to date (SARS-CoV-2, HIV, Chikungunya, Zika, Dengue, etc.) until the end of the regulatory preclinical phases. The preclinical phases of some of these vaccine candidates will be conducted in collaboration with the Institut Pasteur, with the objective of confirming the safety of the vaccine candidates as well as their ability to protect effectively against the virus.

The production of the Covid-19 delta variant vaccine in compliance with GMP standards in Ciloa’s new production facility, will then allow the company to move very quickly towards clinical evaluation.

These advances will confirm the potential of Ciloa’s proprietary exosome platform to create not only vaccines, but also a new generation of therapeutic vectors.

“We are delighted to have received this grant which, coupled to the funds recently raised by Ciloa, ensures our financial visibility for the continued development of our innovative products using exosomes for the treatment or prevention of serious pathologies, which have no effective solution to date”, said Robert Mamoun, CEO and co-founder of Ciloa.

He concluded, “The delta variant is currently the cause of many serious cases of Covid-19. It is essential to rapidly develop efficient protective or therapeutic tools, but also to prepare for the potential emergence of new and more pathogenic variants. Ciloa is also one of the few French biotech companies to have its own exosome production unit, which allow us to move towards clinical phases for the rapid availability of our exosome-based products.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine